182500-28-3

Basic information

• Product Name: 4-bromo-5-methyl-2-nitrophenol
• Synonyms: 4-bromo-5-methyl-2-nitrophenol;2-Nitro-5-methyl-4-bromophenol
• CAS NO: 182500-28-3
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.032
• EINECS: 605-968-3
• Mol File: 182500-28-3.mol

Chemical Properties

• Melting Point: 126℃
• Boiling Point: 293℃
• Flash Point: 131℃
• Appearance: /
• Density: 1.755
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.633
• PKA: 6.46±0.27(Predicted)
• CAS DataBase Reference: 4-bromo-5-methyl-2-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-5-methyl-2-nitrophenol(182500-28-3)
• EPA Substance Registry System: 4-bromo-5-methyl-2-nitrophenol(182500-28-3)

Safety Data

• Hazardous Substances Data: 182500-28-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-bromo-5-methyl-2-nitrophenol is utilized as a key intermediate in the synthesis of various organic compounds. Its unique functional groups allow for a range of chemical reactions, making it a valuable building block for creating new molecules with diverse applications.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-bromo-5-methyl-2-nitrophenol is studied for its potential applications as a starting material or intermediate in the development of new drugs. Its unique structure and reactivity may contribute to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Materials Science:
4-bromo-5-methyl-2-nitrophenol is also explored for its potential use in materials science, where its unique properties could be leveraged to develop new materials with specific characteristics. This may include applications in areas such as polymers, coatings, or advanced materials with tailored properties.

InChI:InChI=1/C7H6BrNO3/c1-4-2-7(10)6(9(11)12)3-5(4)8/h2-3,10H,1H3

Upstream product

• 14472-14-1 4-bromo-3-methylphenol 
• 700-38-9 2-nitro-5-methylphenol 
• 6623-35-4 5-bromo-2-hydroxy-4-methylbenzoic acid 
• 64-19-7 acetic acid 
• 50-85-1 2-hydroxy-p-toluic acid 
• 89978-56-3 1-bromo-4-methoxy-2-methyl-5-nitro-benzene 
• 27060-75-9 4-bromo-3-methylanisole 

Downstream Products

• 602-99-3 3-methyl-2,4,6-trinitrophenol 
• 848359-78-4 4-bromo-3-methyl-2,6-dinitro-phenol 
• 861576-56-9 4-bromo-2-chloro-3-methyl-6-nitro-phenol 
• 848358-81-6 2-amino-4-bromo-5-methylphenol 
• 859937-37-4 2,4-dibromo-3-methyl-6-nitro-phenol 
• 89978-56-3 1-bromo-4-methoxy-2-methyl-5-nitro-benzene 
• 861536-98-3 6-amino-4-bromo-2-chloro-3-methyl-phenol 
• 5456-94-0 2,4-dibromo-5-methylanisole 
• 808133-98-4 5-bromo-2-methoxy-4-methyl-aniline 
• 1035230-16-0 1-bromo-4-isopropoxy-2-methyl-5-nitro-benzene 

Relevant articles and documents

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.